Neuraxis Inc: New Submission to FDA to Expand Label for Ib-Stim Which Would Include Ages 8-21, and 4 Devices Over 4 Weeks
Neuraxis公司:向FDA提交新的申請,拓展Ib-Stim的適應症範圍,該範圍將包括8至21歲年齡段患者,以及4個裝置持續使用4周。
Neuraxis Inc: New Submission to FDA to Expand Label for Ib-Stim Which Would Include Ages 8-21, and 4 Devices Over 4 Weeks
Neuraxis公司:向FDA提交新的申請,拓展Ib-Stim的適應症範圍,該範圍將包括8至21歲年齡段患者,以及4個裝置持續使用4周。
譯文內容由第三人軟體翻譯。